GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Codiak BioSciences Inc (OTCPK:CDAKQ) » Definitions » Median PS Value

Codiak BioSciences (Codiak BioSciences) Median PS Value : $0.00 (As of Jun. 19, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Codiak BioSciences Median PS Value?

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

Median PS Value is calculated as trailing twelve months (TTM) Revenue per Share times 10-Year median PS Ratio. Codiak BioSciences's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 was $1.495. Codiak BioSciences's 10-Year median PS Ratio is 0. Therefore, the Median PS Value for today is $0.00.

As of today (2024-06-19), Codiak BioSciences's share price is $0.0016. Codiak BioSciences's Median PS Value is $0.00. Therefore, Codiak BioSciences's Price to Median PS Value for today is 0.00.

The historical rank and industry rank for Codiak BioSciences's Median PS Value or its related term are showing as below:

CDAKQ's Price-to-Median-PS-Value is not ranked *
in the Biotechnology industry.
Industry Median: 0.65
* Ranked among companies with meaningful Price-to-Median-PS-Value only.

Codiak BioSciences Median PS Value Historical Data

The historical data trend for Codiak BioSciences's Median PS Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Codiak BioSciences Median PS Value Chart

Codiak BioSciences Annual Data
Trend Dec18 Dec19 Dec20 Dec21
Median PS Value
- - - -

Codiak BioSciences Quarterly Data
Dec18 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22
Median PS Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Codiak BioSciences's Median PS Value

For the Biotechnology subindustry, Codiak BioSciences's Price-to-Median-PS-Value, along with its competitors' market caps and Price-to-Median-PS-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Codiak BioSciences's Price-to-Median-PS-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Codiak BioSciences's Price-to-Median-PS-Value distribution charts can be found below:

* The bar in red indicates where Codiak BioSciences's Price-to-Median-PS-Value falls into.



Codiak BioSciences Median PS Value Calculation

Codiak BioSciences's Median PS Value for today is calculated as

Median PS Value=Revenue per Share (TTM)*10-Year Median PS Ratio
=1.495*0
=0.00

10-Year Median PS Ratio is 0.
Codiak BioSciences's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $1.495.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Codiak BioSciences  (OTCPK:CDAKQ) Median PS Value Explanation

This valuation method assumes that the stock valuation will revert to its historical (10-Year) mean in terms of PS Ratio. The reason we use PS Ratio instead of PE Ratio or PB Ratio is because PS Ratio is independent of profit margin, and can be applied to a broader range of situations.

It also assumes that over time the profit margin is constant. If a company increases its profit margin to a sustainable level, this value might under-estimate its value. If it has permanent declined profit margins, this may over-estimate the company's value.

Codiak BioSciences's Price to Median PS Value for today is calculated as

Price to Median PS Value=Share Price/Median PS Value
=0.0016/0.00
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Codiak BioSciences Median PS Value Related Terms

Thank you for viewing the detailed overview of Codiak BioSciences's Median PS Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Codiak BioSciences (Codiak BioSciences) Business Description

Traded in Other Exchanges
N/A
Address
35 Cambridge Park Drive, Suite 500, Cambridge, MA, USA, 02140
Codiak BioSciences Inc is a development-stage biopharmaceutical company focused on the development of exosome-based therapeutics for the treatment of a wide spectrum of diseases with high unmet medical need. The company have utilized engEx Platform to generate a pipeline of engineered exosomes, aimed at treating a broad range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease, infectious disease and rare disease.
Executives
Yalonda Howze officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Sriram Sathyanarayanan officer: Chief Scientific Officer C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Nicole Barna officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Douglas E Williams director, officer: President & CEO C/O AMGEN INC, ONE AMGEN CENTER DR, THOUSAND OAKS CA 91320-1799
Linda Bain officer: Chief Financial Officer C/O BLUEBIRD BIO, INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Konstantin Konstantinov officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 500 TECHNOLOGY SQUARE, 9TH FLOOR, CAMBRIDGE MA 02139
Arch Venture Fund Viii Overage, L.p. 10 percent owner C/O ARCH VENTURE PARTNERS VIII, LLC, 8755 W. HIGGINS ROAD, SUITE 1025, CHICAGO IL 60631
David J Mauro officer: Chief Medical Officer 36 TERRELL DRIVE, WASHINGTON CROSS PA 18977
Arundathy N. Pandite director 1018 W 11TH ST., SUITE 100, AUSTIN TX 78703
Benny Sorensen officer: See Remarks C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Anne-virginie Eggimann director C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Jennifer J. Wheler officer: Chief Medical Officer C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Briggs Morrison director C/O SYNDAX PHARMACEUTICALS, INC., 400 TOTTEN POND ROAD, SUITE 110, WALTHAM MA 02451
Alaska Permanent Fund Corp 10 percent owner 801 WEST 10TH STREET, SUITE 302, JUNEAU AK 99801
Flagship Ventures Fund V, L.p. 10 percent owner ONE MEMORIAL DRIVE, 7TH FLOOR, CAMBRIDGE MA 02142